Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.9 USD | +3.18% | +7.47% | -19.27% |
Apr. 26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.27% | 30.42B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- RBC Cuts Price Target on Biogen to $364 From $379 Amid Q4 Miss, Keeps Outperform Rating